GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Swiss Medical Weekly, SMW Supporting Association
    Type of Medium: Online Resource
    ISSN: 1424-3997
    Language: English
    Publisher: SMW Supporting Association
    Publication Date: 2019
    detail.hit.zdb_id: 2031164-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Swiss Medical Weekly, SMW Supporting Association, Vol. 151, No. 0910 ( 2021-03-01), p. w20464-
    Abstract: BACKGROUND International guidelines state that bone-targeted agents such as denosumab or zoledronic acid at doses used for bone metastasis are not indicated for patients with metastatic castration-sensitive prostate cancer (mCSPC) with bone metastases. Whereas denosumab has never been studied in this patient population, zoledronic acid has been shown to be ineffective in decreasing the risk for skeletal-related events. This study estimates the prevalence and economic consequences of real-world use of bone-targeted agents for mCSPC patients in Switzerland. METHODS To estimate the frequency of bone-targeted agent administration and skeletal-related events, data from a non-interventional, cross-sectional survey involving oncologists across Switzerland (SAKK 95/16) was combined with data from the Swiss National Institute for Cancer Epidemiology and Registration (NICER). Economic parameters were calculated from the perspective of the healthcare system over the median time to prostate-specific antigen (PSA) progression for the extrapolated patient group, using data from NICER. The cost calculation covered costs for bone-targeted agents, their administration and skeletal-related events. The time to PSA progression (33.2 months), as well as the probability and cost of skeletal-related events were derived from the literature. RESULTS The survey was answered by 86 physicians treating 417 patients, of whom 106 (25.4%) had prostate cancer, with 36 (34.0%) of these mCSPC. The majority of mCSPC patients (52.8%, n = 19) received bone-targeted agents monthly. Denosumab was the treatment of choice in 84.2% of patients (n = 16). Extrapolation using data from NICER indicated that 568 mCSPC patients may be treated with bone-targeted agents at doses used for bone metastasis every year in Switzerland, leading to estimated total costs of more than CHF 8.3 million over 33.2 months. Because of its more frequent prescription and higher price, it appears that almost 93% of the total costs can be attributed to denosumab. For both denosumab and zoledronic acid, the most expensive components were the cost of administration and the drug cost, making up more than 90% of the total costs, with the rest being costs of skeletal-related events. CONCLUSIONS This study found that the administration of bone-targeted agents in doses used for bone-metastatic diseases to prevent skeletal-related events is frequent in the setting of mCSPC and results in significant costs for the healthcare system.
    Type of Medium: Online Resource
    ISSN: 1424-3997
    Language: Unknown
    Publisher: SMW Supporting Association
    Publication Date: 2021
    detail.hit.zdb_id: 2031164-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Swiss Medical Weekly, SMW Supporting Association, Vol. 151, No. 3536 ( 2021-09-01), p. w30018-
    Abstract: OBJECTIVE: To analyse utilisation patterns of lipid-lowering drugs and the related costs in Switzerland between the years 2013 and 2019. METHODS: We conducted a retrospective descriptive study using administrative claims data of persons aged ≥18 years enrolled with the health insurance company Helsana. To enable statements at the Swiss population level, results were extrapolated according to age, sex and canton of residence. RESULTS: The overall prevalence of patients taking lipid-lowering drugs rose from 8.9% (n = 736,174) in 2013 to 11.6% (n = 841,682) in 2019, but varied markedly across regions, with highest values in Ticino and lowest values in Zurich. More than every third individual aged ≥65 years was treated with a lipid-lowering drug in 2019. Statins were by far the most commonly used drugs ( 〉 90% of prescriptions), followed by ezetimibe, fibrates and PCSK9 inhibitors. We observed a trend towards the prescription of more potent statins (atorvastatin, rosuvastatin) in recent years. Total costs of lipid-lowering drugs increased from CHF 222 million in 2013 to CHF 230 million in 2019 (+3.5%), whereas annual per capita costs decreased from CHF 302 in 2013 to CHF 273 in 2019 (−9.4%). CONCLUSION: The increasing use of lipid-lowering drugs reflects current therapeutic guidelines, but results in high costs for the healthcare system.
    Type of Medium: Online Resource
    ISSN: 1424-3997
    Language: Unknown
    Publisher: SMW Supporting Association
    Publication Date: 2021
    detail.hit.zdb_id: 2031164-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Swiss Medical Weekly, SMW Supporting Association
    Type of Medium: Online Resource
    ISSN: 1424-3997
    Language: English
    Publisher: SMW Supporting Association
    Publication Date: 2019
    detail.hit.zdb_id: 2031164-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Swiss Medical Weekly, SMW Supporting Association, Vol. 152, No. 1112 ( 2022-03-24), p. w30135-
    Abstract:   AIMS OF THE STUDY: Multimorbidity is a growing global health problem, resulting in an increased perioperative risk for surgical patients. Data on both the prevalence of multimorbidity and its impact on perioperative outcome are limited. The American Society of Anesthesiologists (ASA) classification uses only the single most severe systemic disease to define the ASA class and ignores multimorbidity. This study aimed to assess the number and type of all anaesthesia-relevant comorbidities and to analyse their impact on outcome and hospital costs. METHODS: This cohort study is nested in the ClassIntra® validation study and includes only patients enrolled at the University Hospital of Basel. Approximately 30 patients per surgical discipline undergoing any type of in-hospital surgery were followed up until hospital discharge to record all intra- and postoperative adverse events. In addition, the type and severity of all perioperatively relevant comorbidities were extracted from the electronic medical record according to a predefined list. The primary endpoint was the number of all anaesthesia-relevant comorbidities by ASA class. Using structural equation models, the direct and indirect effects of comorbidities on costs were estimated after adjustment for the ASA class and further relevant confounders and mediators. RESULTS: Of 320 enrolled patients, 27 were ASA I (8%), 150 ASA II (47%), 116 ASA III (36%) and 27 ASA IV (8%). The median number of comorbidities per patient was 5 (range 0–18), this number significantly increasing with higher ASA class: 1 comorbidity (95% CI 0.0–2.0) in ASA I, 4 comorbidities (3.8–4.2) in ASA II, 9 (8.1–9.9) in ASA III and 12 (10–14) in ASA IV patients. Independent of ASA class, each additional comorbidity increased hospital costs by EUR 1,198 (95% CI 288–2108) with almost identical proportions of direct and indirect effects. The number of anaesthesia-relevant comorbidities also increased postoperative complications and postoperative length of hospital stay. CONCLUSIONS: Multimorbidity in perioperative patients is highly prevalent and has a relevant impact on hospital costs, independent of the ASA class. Incorporating multimorbidity into the ASA classification might be warranted to improve its predictive ability and support adequate reimbursement. The ClassIntra® validation study had been registered on ClinicalTrials.gov (NCT03009929).
    Type of Medium: Online Resource
    ISSN: 1424-3997
    Language: Unknown
    Publisher: SMW Supporting Association
    Publication Date: 2022
    detail.hit.zdb_id: 2031164-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Swiss Medical Weekly, SMW Supporting Association, Vol. 152, No. 0304 ( 2022-01-28), p. w30125-
    Abstract: BACKGROUND: Patients in intensive care units (ICUs) are at high risk of developing physical, functional, cognitive, and mental impairments. Early mobilisation aims to improve patient outcomes and is increasingly considered the standard of care. This survey aimed to investigate the characteristics, current use and variations of early mobilisation and rehabilitation in Swiss ICUs. METHODS: We conducted a cross-sectional survey among all ICU lead physicians, who provided data on their institutional characteristics, early mobilisation and rehabilitation practices, and their perceptions of the use and variation of early rehabilitation practices in Switzerland. RESULTS: The survey response rate was 44% (37/84). Among ICUs caring for adults (34/37), 26 were in the German-speaking region, five in the French-speaking region, and three in the Italian-speaking region. All ICUs regularly involved physiotherapy in the rehabilitation process and 50% reported having a specialised physiotherapy team. All ICUs reported performing early mobilisation, starting within the first 7 days after ICU admission. About half reported the use of a rehabilitation (45%) or early mobilisation protocol (50%). Regular, structured, interdisciplinary rounds or meetings of the ICU care team to discuss rehabilitation measures and goals for patients were stated to be held by 53%. The respondents stated that 82% of their patients received early mobilisation measures during their ICU stay. Most frequently provided mobilisation measures included passive range of motion (97%), passive chair position in bed (97%), active range of motion muscle activation and training (88%), active side to side turning (91%), sitting on the edge of the bed (94%), transfer from bed to a chair (97%), and ambulation (94%). The proportion of ICUs providing a specific early mobilisation measure, the proportion of patients receiving it, and the time dedicated to it varied across language regions, hospital types, ICU types, and ICU sizes. Almost one third of the ICU lead physicians considered early rehabilitation to be underused in their own ICU and about half considered it to be underused in Switzerland more generally. ICU lead physicians stressed lack of personnel, financial resources, and time as key causes for underuse. Moreover, they highlighted the importance of early and systematic or protocol-based rehabilitation and interprofessional approaches that are adaptive to the patients' rehabilitation needs and potential. CONCLUSION: This survey suggests that almost all ICUs in Switzerland practice some form of early mobilisation with the aim of early rehabilitation. However, the described approaches, as well as the reported use of early mobilisation measures were heterogenous across Swiss ICUs.
    Type of Medium: Online Resource
    ISSN: 1424-3997
    Language: Unknown
    Publisher: SMW Supporting Association
    Publication Date: 2022
    detail.hit.zdb_id: 2031164-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Swiss Medical Weekly, SMW Supporting Association
    Type of Medium: Online Resource
    ISSN: 1424-3997
    Language: English
    Publisher: SMW Supporting Association
    Publication Date: 2017
    detail.hit.zdb_id: 2031164-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Swiss Medical Weekly, SMW Supporting Association
    Type of Medium: Online Resource
    ISSN: 1424-3997
    Language: English
    Publisher: SMW Supporting Association
    Publication Date: 2018
    detail.hit.zdb_id: 2031164-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Swiss Medical Weekly, SMW Supporting Association, Vol. 151, No. 3334 ( 2021-08-23), p. w30022-
    Abstract: BACKGROUND: The incidence of influenza and influenza-like illnesses in Switzerland is generally high. Although related direct medical costs can be substantial, especially if hospitalisations occur, several studies suggested that indirect costs due to the loss of productivity may represent an even higher economic burden. The aim of this study was to assess the costs arising from lost productivity due to influenza and influenza-like illnesses in Switzerland. METHODS: Analyses were based on data collected in 2016 and 2017 by the Swiss Sentinel Surveillance Network of the Swiss Federal Office of Public Health (SFOPH). The available information covered details on the physicians collecting the data, patients’ characteristics, symptoms, treatments, and inability to work (in terms of physician-recorded workdays lost for own sickness or caregiving). The cost of lost productivity, estimated using the human capital approach, was calculated as the number of workdays lost due to influenza-like illnesses multiplied by the mean salary for one working day. Salary differences across sex, age and region were considered. Extrapolation to the national level was performed by adjusting for the size of the Swiss population, the age and sex distribution, the regional distribution, the number of Sentinel general physician contacts and the specialisation of the physician. RESULTS: At the Swiss national level, the estimated total yearly number of cases of inability to work due to influenza and influenza-like illnesses was 101,287 in 2016 and 86,373 in 2017. In subgroups defined by year, gender, region and age class, numbers of cases per 100,000 inhabitants ranged from 12 to 2396. The total number of workdays lost in Switzerland, considering degree of employment and visit day, were estimated to be 324,118 in 2016 and 278,121 in 2017. The number of workdays lost was generally higher in men (53.7% of the total in 2016 and 55.6% of the total in 2017) than women. The estimated total costs due to inability to work, calculated using a human capital approach and including the caregiving costs, were CHF 115 million in 2016 and CHF 103 million in 2017, equivalent to CHF 1.4 million per 100,000 inhabitants. CONCLUSION: The costs of lost productivity due to influenza and influenza-like illnesses in Switzerland are substantial and may vary considerably between different years, regions and age classes. As the present analyses could not consider all causes of lost productivity (e.g., short-term inability to work not requiring a physician consultation, hospitalisations, early retirement, premature death), the total indirect costs due to influenza or influenza-like illnesses can be expected to be higher than the presented estimates.
    Type of Medium: Online Resource
    ISSN: 1424-3997
    Language: Unknown
    Publisher: SMW Supporting Association
    Publication Date: 2021
    detail.hit.zdb_id: 2031164-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Swiss Medical Weekly, SMW Supporting Association
    Type of Medium: Online Resource
    ISSN: 1424-3997
    Language: English
    Publisher: SMW Supporting Association
    Publication Date: 2019
    detail.hit.zdb_id: 2031164-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...